
Zanidatamab Nets European Approval in Pretreated HER2+ Biliary Tract Cancer
The HER2-directed bispecific antibody zanidatamab-hrii (Ziihera) has received conditional marketing authorization from the European Commission (EC) for the treatment of adult patients with unresectable locally advanced or metastatic HER2-positive ( …